8-K Announcements
6Material company update
Mar 13, 2026·SEC
Material company update
Jan 27, 2026·SEC
Material company update
Jan 9, 2026·SEC
Savara Inc.(SVRA)Earnings, Financials & Key Ratios
SVRA•NASDAQ
$5.90
Price updated Jun 27, 2026
AboutSavara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.Show more
- Revenue$0
- EBITDA-$123M-19.6%
- Net Income-$119M-23.9%
- EPS (Diluted)-0.53-10.4%
- ROE-63.45%-3.2%
SVRA Price & Volume
Savara Inc. (SVRA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Cash Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial outcome
"Savara remains in a high-risk, binary-outcome phase as it advances the IMPALA-2 clinical trial, with quarterly R&D expenditures escalating to $23.4 million as of 2026Q1. The company's reliance on equity-based incentives and potential future capital raises creates significant dilution risk for current shareholders. Investors should monitor the firm's ability to manage its $39.0 million quarterly operating loss against a tightening liquidity position of $38.8 million in cash."
Verdict Logic
the company's $38.8 million cash balance is insufficient to cover the current quarterly operating loss of $39.0 million, suggesting an imminent need for dilutive financing.
SVRA Growth Metrics
Savara Inc. (SVRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-26.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-14.29%
Return on Capital
10 Years-43.64%
5 Years-42.59%
3 Years-51.24%
Last Year-57.3%
SVRA Recent Earnings
Savara Inc. (SVRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (8%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
—
$500,000
Q2 2026
May 12, 2026Metric
Actual
Est
EPS
$0.15-7.1%
$0.14
Rev
—
$500,000
Q2 2026
Mar 13, 2026Metric
Actual
Est
EPS
$0.13-8.3%
$0.12
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.14-7.7%
$0.13
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.15vs $0.14-7.1% | —vs $500,000 |
| Q2 2026 | May 12, 2026 | $0.15vs $0.14-7.1% | —vs $500,000 |
| Q2 2026 | Mar 13, 2026 | $0.13vs $0.12-8.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.14vs $0.13-7.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Savara Inc. (SVRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.90 | $1.21B | -11.13 | — | — | -63.45% | — | |
| $103.38 | $22.41B | -16.13 | 66.73% | -144.44% | -130.11% | — | |
| $17.63 | $908.88M | 8.56 | 66.92% | 104.34% | 43.85% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $4.14 | $1.28B | 207.00 | 22.23% | -6.63% | — | — | |
| $16.33 | $19.02B | -5.44 | -2.98% | -2.04% | -1.97% | — |
Compare SVRA vs Peers
Savara Inc. (SVRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SVRA SEC Filings & Documents
Savara Inc. (SVRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SVRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SVRA Frequently Asked Questions
Savara Inc. (SVRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SVRA profitable?
Savara Inc. (SVRA) reported a net loss of $129.5M for fiscal year 2025.
Dividend & Returns
What is SVRA's return on equity?
Savara Inc. (SVRA) has a return on equity (ROE) of -63.5%. Negative ROE indicates the company is unprofitable.
What is Savara Inc.'s free cash flow?
Savara Inc. (SVRA) had negative free cash flow of $107.0M in fiscal year 2025, likely due to heavy capital investments.